Pacific Biosciences AI Stock Analysis
Pacific Biosciences (P09) AI Stock Analysis
Pacific Biosciences
(XETRA:P09)
No summary available
Pacific Biosciences (P09) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 568.27M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,266
- Price to Earnings (P/E)
- -4.4
- Beta (1Y)
- 0.09
- Revenue Growth
- -0.79%
- EPS Growth
- 76.78%
- Country
- Germany
- Employees
- 485
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Pacific Biosciences Business Overview & Revenue Model
Company Description
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the p...
Pacific Biosciences Earnings Call Summary
The call was broadly positive, with improving SPRQ-Nx adoption, clinical growth above 20% year-over-year, stronger instrument placements, strategic clinical and AI partnerships, and continued progress toward operating expense reduction and a 2028 cash flow breakeven target. These positives were tempered by lower year-over-year consumables revenue, a decline in gross margin, constrained academic and government funding, a reduced cash balance, and ongoing regional and capital-spending challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
PacBio is narrowing full year revenue guidance to $155 million to $160 million, expects non-GAAP gross margin to be in the range of 35% to 37% for 2026, year-end cash of approximately $175 million to $185 million, and non-GAAP operating expenses in the range of $203 million to $207 million; it continues to expect full year consumables pull-through of $200,000 to $225,000 per Revio system, the vast majority of the installed base to opt in by year-end, cash burn to step down meaningfully in 2027, $15 million to $20 million in expected annual savings from reduced compensation-related expenses, an additional $15 million to $20 million in annual savings as development spending on the high throughput platform widens down, cash flow breakeven in 2028, a return back to that 225 to 250 pull-through range for consumables in 2027, and a commercial launch of the high throughput platform by the end of next year.
Pacific Biosciences Risk Analysis
Pacific Biosciences disclosed 66 risk factors in its most recent earnings report. Pacific Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskPacific Biosciences Peers Comparison
Overall Rating
BIO78Outperform
BRKR57Neutral
CTKB53Neutral
QSI50Neutral
QTRX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $9.73B | 9.41 | 14.07% | ― | 1.38% | ― | |
| 57Neutral | $9.37B | -55.94 | -5.15% | 0.33% | 2.16% | -604.24% | |
| 53Neutral | $745.47M | -9.02 | -24.74% | ― | 5.50% | -524.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $221.94M | -2.57 | -44.72% | ― | -60.18% | 40.20% | |
| 40Underperform | $135.79M | -1.21 | -42.99% | ― | 13.78% | -1.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:P09 | Pacific Biosciences | 1.65 | 0.26 | 18.49% | |
| BIO | Bio-Rad Laboratories | 358.19 | 53.40 | 17.52% | |
| BRKR | Bruker Corporation | 61.36 | 18.15 | 42.02% | |
| QTRX | Quanterix | 2.86 | -3.00 | -51.19% | |
| QSI | Quantum-Si Incorporated | 1.01 | -0.27 | -21.09% | |
| CTKB | Cytek Biosciences, Inc. | 5.70 | 0.44 | 8.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
